First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Stock Price Up 1.6% – Time to Buy?

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH)’s share price was up 1.6% during trading on Thursday . The stock traded as high as $38.59 and last traded at $38.52. Approximately 14,818 shares were traded during mid-day trading, an increase of 30% from the average session volume of 11,400 shares. The stock had previously closed at $37.92.

First Trust Nasdaq Pharmaceuticals ETF Trading Up 0.3%

The stock has a market capitalization of $36.72 million, a PE ratio of 14.51 and a beta of 0.45. The firm’s fifty day moving average price is $36.20 and its two-hundred day moving average price is $34.85.

First Trust Nasdaq Pharmaceuticals ETF Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Thursday, June 25th were given a $0.092 dividend. This represents a $0.37 dividend on an annualized basis and a dividend yield of 1.0%. This is an increase from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.06. The ex-dividend date was Thursday, June 25th.

Hedge Funds Weigh In On First Trust Nasdaq Pharmaceuticals ETF

Institutional investors and hedge funds have recently modified their holdings of the business. LPL Financial LLC boosted its position in First Trust Nasdaq Pharmaceuticals ETF by 40.5% during the fourth quarter. LPL Financial LLC now owns 146,105 shares of the company’s stock worth $4,813,000 after purchasing an additional 42,147 shares in the last quarter. Marshall Investment Management LLC acquired a new position in shares of First Trust Nasdaq Pharmaceuticals ETF during the 4th quarter worth approximately $1,377,000. Goldman Sachs Group Inc. raised its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 11.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 19,472 shares of the company’s stock worth $535,000 after buying an additional 2,047 shares during the period. Envestnet Asset Management Inc. lifted its position in shares of First Trust Nasdaq Pharmaceuticals ETF by 2.1% during the 3rd quarter. Envestnet Asset Management Inc. now owns 18,132 shares of the company’s stock valued at $517,000 after buying an additional 367 shares in the last quarter. Finally, OLD Mission Capital LLC purchased a new position in shares of First Trust Nasdaq Pharmaceuticals ETF during the 4th quarter valued at approximately $528,000.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.